WDR51A Inhibitors
WDR51A inhibitors encompass a diverse array of chemical compounds that act through various cellular pathways to inhibit the functional activity of the WDR51A protein. Protein kinase inhibitors like staurosporine exert their effect by targeting kinases that may phosphorylate proteins associated with WDR51A, thereby impacting its role within the cell. Other kinase-targeting agents, including LY 294002 and wortmannin, function similarly by disrupting the PI3K/AKT pathway, potentially altering the regulation of WDR51A-associated proteins in signaling or trafficking. Rapamycin, through mTOR pathway inhibition, and proteasome inhibitors such as bortezomib and MG-132, may affect WDR51A functionality by modulating processes like protein synthesis, autophagy, and protein turnover that WDR51A is suspected to be involved with. These inhibitors collectively contribute to a decrease in WDR51A activity by influencing pathways and processes that are critical to its function.
Further, compounds like PD 98059, SB 203580, SP600125, and U0126 specifically target the MAPK signaling cascade, indirectly leading to the diminishment of WDR51A function by affecting the ERK,p38, and JNK pathways, which could regulate WDR51A-involved interactions. The perturbation of these pathways by such inhibitors may result in altered cellular stress responses or other regulatory mechanisms where WDR51A may play a role. Additionally, Thapsigargin and Cyclosporin A inadvertently inhibit WDR51A by disrupting calcium homeostasis and calcineurin activity, respectively, affecting calcium-dependent signaling pathways that WDR51A could be part of. The resulting alteration in signaling equilibria due to these inhibitors potentially leads to a reduction in WDR51A's involvement in these processes. Overall, WDR51A inhibitors function by a combination of kinase inhibition, disruption of signaling pathways, and modulation of cellular homeostasis mechanisms, thereby collectively contributing to the indirect inhibition of WDR51A's functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent non-selective inhibitor of protein kinases, staurosporine can result in the indirect inhibition of WDR51A protein function by suppressing the activity of kinases that phosphorylate proteins interacting with WDR51A, thus affecting its role in the cellular processes it is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, LY 294002 can indirectly diminish the functional activity of WDR51A by blocking the PI3K/AKT pathway, which is potentially involved with the regulation of proteins that associate with WDR51A in cellular signaling or trafficking processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, rapamycin can lead to an indirect decrease in WDR51A function by inhibiting mTOR signaling, which might be involved in regulating cellular processes that WDR51A is associated with, such as protein synthesis and autophagy. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, and its action could indirectly lead to decreased WDR51A activity by inhibiting downstream signaling pathways that WDR51A may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As a specific inhibitor of MEK, PD 98059 indirectly inhibits the ERK/MAPK pathway, which could be involved in the regulation of protein interactions or functions where WDR51A plays a role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By selectively inhibiting p38 MAPK, SB 203580 can indirectly affect WDR51A function by altering the cellular stress response or other p38 MAPK-regulated processes that might implicate WDR51A. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can indirectly inhibit WDR51A activity through the stress-activated MAPK pathway, which might intersect with biological processes WDR51A is involved in. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), thapsigargin can indirectly inhibit WDR51A by disrupting calcium homeostasis, which could affect calcium-dependent signaling pathways that involve WDR51A. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, bortezomib can indirectly decrease WDR51A function by preventing the degradation of regulatory proteins that could interact with WDR51A in cellular quality control mechanisms. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Anproteasome inhibitor, MG-132 can lead to the indirect inhibition of WDR51A function by stabilizing proteins that may be involved in the same biological processes as WDR51A, such as protein turnover and signaling. | ||||||